BIPHETAMINE 20
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Sep 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIPHETAMINE 20 is an oral extended-release capsule containing amphetamine salts, approved since 1955 for treating attention and behavioral disorders. The drug is a sympathomimetic amine that acts as a central nervous system stimulant. Patient population includes individuals diagnosed with attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); commercial team likely in transition planning and lifecycle extension mode rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings reflect BIPHETAMINE 20's mature lifecycle and approaching LOE, limiting organic hiring. Career opportunities lie in defensive strategies, generic competition management, and lifecycle extension—roles suited to experienced commercial or regulatory professionals rather than growth-stage positions.
Brand ManagerField Sales
Worked on BIPHETAMINE 20 at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.